Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-Mutated Acute Myeloid Leukemia (AML) from Blast Crisis Chronic Myelogenous Leukemia (BC-CML)

Vanessa E. Kennedy, Cheryl A C Peretz, Andrew Koh, Elaine Tran, Dalia Dhingra, Saurabh Gulati, Adam Sciambi, Olga Sala-Torra, Lan Beppu, Aaron C. Logan, Alexander Perl, Wendy Stock, Geoffrey L Uy, Ann-Kathrin Eisfeld, Jerald P. Radich, Catherine C. Smith

Blood (2023) 142 (Supplement 1): 4334.

https://doi.org/10.1182/blood-2023-182454

Published: 2023

Journal Articles

Rapid Clinical Mutation Screening for AML Using the Genexus Platform

Shahanawaz Jiwani, Jerald P. Radich, Maria Saeed, Lauri Aicher, Ting-Chia Chang, Srikrishna Narava, Zaneta Holman, Lan Beppu, Olga Sala-Torra, Marvin Majano, Erin Taylor, Laura Yee, Jessica Li, Lisa McShane, Pooja CS Sanduria, Paul Mickey M. Williams, Cecilia C.S. Yeung

Blood (2023) 142 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2023-188270

Published: 2023

Journal Articles

Minimally Invasive Blood Sampling for BCR::ABL1 transcript Monitoring

Vivian G. Oehler, Olga Sala-Torra, Qian Vicky Wu, Lan Beppu, Emily Welch, Erwin Berthier, Jerald P. Radich

Blood (2022) 140 (Supplement 1): 3883–3884.

https://doi.org/10.1182/blood-2022-167799

Published: 2022

Journal Articles

Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report

Blood (2021) 138 (Supplement 1): 522.

https://doi.org/10.1182/blood-2021-151246

Published: 2021

Journal Articles

Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG

Blood (2021) 138 (Supplement 1): 799.

https://doi.org/10.1182/blood-2021-151678

Published: 2021

Journal Articles

Clonal Hematopoiesis in Donor-Recipient Pairs after Allogeneic Hematopoietic Cell Transplantation

Masumi Ueda, MD, Lan Beppu, Judy Campbell, RN, Mary E. D. Flowers, MD, Jerald P. Radich, MD, Rainer Storb, MD

Blood (2019) 134 (Supplement_1): 702.

https://doi.org/10.1182/blood-2019-126979

Published: 2019

Journal Articles

Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Blood (2016) 128 (22): 1119.

https://doi.org/10.1182/blood.V128.22.1119.1119

Published: 2016

Journal Articles

A Novel Somatic Mutation in IKZF1 Is Common in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for Myelofibrosis

Emily Stevens, MD PhD, Isaac C Jenkins, MS, Lan Beppu, BS, Qing Zhang, Keith R Loeb, MD PhD, Rachel Salit, MD, Jerald P. Radich, MD, H. Joachim Deeg, MD

Blood (2016) 128 (22): 1961.

https://doi.org/10.1182/blood.V128.22.1961.1961

Published: 2016

Journal Articles

Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots

Olga Sala Torra, Lan Beppu, Jordan L. Smith, Linda Welden, Jasmina Georgievski, Karisma Gupta, Rashmi Kumar, Cecilia C. S. Yeung, Amy Paguirigan, Ted A. Gooley, Susan Branford, Jerald P. Radich

Blood (2016) 127 (22): 2773–2774.

https://doi.org/10.1182/blood-2015-12-689059

Published: 2016

Includes: Supplemental data

Journal Articles

Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

Michael W. Schmitt, MD PhD, Justin R. Pritchard, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Bella I. Aminov, Lan Beppu, Lawrence A. Loeb, MD PhD, Jerald P. Radich

Blood (2015) 126 (23): 478.

https://doi.org/10.1182/blood.V126.23.478.478

Published: 2015

Journal Articles

Paper or Plastic: RT-PCR of BCR-ABL from Blood Spots Stored and Shipped on Paper

Olga Sala Torra, MD, Lan Beppu, Susan Branford, PhD, Linda Fletcher, BS, Gooley Ted, PhD, Amy L Paguirigan, PhD, Jordan Smith, Jerald P Radich, MD

Blood (2014) 124 (21): 4566.

https://doi.org/10.1182/blood.V124.21.4566.4566

Published: 2014

Journal Articles

Patients With Philadelphia-Positive Leukemia With BCR-ABL Kinase Mutations Prior To Allogeneic Transplantation Predominantly Relapse With The Same Mutation

Daniel N. Egan, MD, Lan Beppu, Jerald Radich, MD

Blood (2013) 122 (21): 4043.

https://doi.org/10.1182/blood.V122.21.4043.4043

Published: 2013

Journal Articles

Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib – A TOPS Correlative Substudy

Blood (2010) 116 (21): 670.

https://doi.org/10.1182/blood.V116.21.670.670

Published: 2010

Journal Articles

A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate

Susan Branford, PhD, Hyun-Gyung Goh, Barbara Izzo, Lan Beppu, Christine-Elke Ortmann, Kamila Duniec, PhD, Yu Jin, Richard C. Woodman, MD, Fabrizio Pane, MD, Dong-Wook Kim, Jerald P. Radich, MD, Timothy P. Hughes

Blood (2010) 116 (21): 889.

https://doi.org/10.1182/blood.V116.21.889.889

Published: 2010

Journal Articles

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Jerald P. Radich, MD, Giovanni Martinelli, MD, Andreas Hochhaus, MD, Enrico Gottardi, Simona Soverini, PhD, Susan Branford, PhD, Martin C Müller, MD, Lan Beppu, Yaping Shou, MD, PhD, Ariful Haque, MS, Richard C. Woodman, MD, Hagop M. Kantarjian, MD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Giuseppe Saglio, MD

Blood (2009) 114 (22): 1130.

https://doi.org/10.1182/blood.V114.22.1130.1130

Published: 2009

Journal Articles

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Susan Branford, PhD, Dong-Wook Kim, MD, PhD, Simona Soverini, PhD, Enrico Gottardi, Lan Beppu, Martin C Müller, MD, Ariful Haque, MS, Yaping Shou, MD, PhD, Richard C. Woodman, MD, Hagop M. Kantarjian, MD, Giovanni Martinelli, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD

Blood (2009) 114 (22): 3292.

https://doi.org/10.1182/blood.V114.22.3292.3292

Published: 2009

Journal Articles

Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.

Blood (2009) 114 (22): 3283.

https://doi.org/10.1182/blood.V114.22.3283.3283

Published: 2009

Journal Articles

The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation

Jerald P. Radich, Ted Gooley, Eileen Bryant, Tom Chauncey, Reginald Clift, Lan Beppu, Scott Edmands, Mary E. D. Flowers, Keith Kerkof, Ross Nelson, Frederick R. Appelbaum

Blood (2001) 98 (6): 1701–1707.

https://doi.org/10.1182/blood.V98.6.1701

Published: 2001

NARROW

Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-Mutated Acute Myeloid Leukemia (AML) from Blast Crisis Chronic Myelogenous Leukemia (BC-CML)

Rapid Clinical Mutation Screening for AML Using the Genexus Platform

Minimally Invasive Blood Sampling for BCR::ABL1 transcript Monitoring

Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report

Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG

Clonal Hematopoiesis in Donor-Recipient Pairs after Allogeneic Hematopoietic Cell Transplantation

Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

A Novel Somatic Mutation in IKZF1 Is Common in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for Myelofibrosis

Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots

Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

Paper or Plastic: RT-PCR of BCR-ABL from Blood Spots Stored and Shipped on Paper

Patients With Philadelphia-Positive Leukemia With BCR-ABL Kinase Mutations Prior To Allogeneic Transplantation Predominantly Relapse With The Same Mutation

Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib – A TOPS Correlative Substudy

A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.

The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only